Novo Nordisk’s pill could be first oral GLP-1 RA therapy for children and adolescents with T2D
Novo Nordisk today announced positive topline results from a Phase III trial evaluating oral semaglutide for type 2…
Novo Nordisk withstands stiff generic competition post semaglutide patent expiry in India in March, 26 brands from 13 firms launched
Danish drug major Novo Nordisk seems to be withstanding stiff competition from generic players after its global blockbuster…
Novo Nordisk Faces Mounting Challenges on Pricing and Pipeline
Novo Nordisk slashes US prices for Ozempic, Wegovy, and Rybelsus to $675/month in 2027. Its new obesity drug,…
Novo Nordisk announces significant reduction in U.S. list price for Wegovy, Ozempic, and Rybelsus
Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale…